Prasinezumab (PRX 002) 是一种针对聚集的 α-突触核蛋白 (α-synuclein) 的人源化 IgG1 单克隆抗体。Prasinezumab 具有用于帕金森病研究的潜力。
| 生物活性 | Prasinezumab (PRX 002) is a humanizedIgG1monoclonal antibody directed against aggregatedα-synuclein. Prasinezumab has the potential for Parkinson's disease research[1]. |
体外研究
(In Vitro) | Prasinezumab 针对人 α-突触核蛋白羧基末端的表位。 Prasinezumab 以高亲和力与人类聚集的 α-突触核蛋白结合[1]。
|
| CAS 号 | |
| 中文名称 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
